General Statement of Disclosure:
CONSULTING FEES/HONORARIA: Alnylam(SIGNIFICANT), Novo Nordisk Inc.(SIGNIFICANT), Pfizer Inc(SIGNIFICANT), BridgeBio(SIGNIFICANT), Alexion(SIGNIFICANT), AstraZeneca Pharmaceuticals(SIGNIFICANT)
CONSULTING FEES/HONORARIA: Alnylam(SIGNIFICANT), Novo Nordisk Inc.(SIGNIFICANT), Pfizer Inc(SIGNIFICANT), BridgeBio(SIGNIFICANT), Alexion(SIGNIFICANT), AstraZeneca Pharmaceuticals(SIGNIFICANT)
© 2026 American College of Cardiology Foundation. All rights reserved.
